As per MRFR analysis, the Cell Viability Assays Market Size was estimated at 2.24 (USD Billion) in 2024. The Cell Viability Assays Market Industry is expected to grow from 2.43 (USD Billion) in 2025 to 5.05 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 8.50% during the forecast period (2025 - 2034). Increasing investment in healthcare infrastructure and increasing expertise in research and development to advance technologies are the key market drivers enhancing the growth of the studied market. 
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Twenty-five million US dollars were invested in InSphero, a company that makes microfluidic 3D cell culture systems for drug development and personalized medicine F. Hoffmann- La Roche in January 2024.
Cytiva, a leading supplier of life science technologies, was acquired by Danaher Corporation in October 2023 for $21.4 billion doubling its shares in the cell-based assay market through expanding its bioprocessing technology portfolio and cell culture technology.Thermo Fisher Scientific launched the Genedrive platform as a fully automated cellular test system for high-throughput drug discovery and personalized medicine applications in October 2023.September 2022: Nanolive introduces LIVE Cell Death Assay – an automated method for profiling cell health, death (apoptosis), apoptosis and necrosis.For example, PubMed Central published an article in May 2022 that showed how real-time cellular viability can be monitored using supervised machine learning via label-free, non-invasive, non-destructive intracellular dynamics. However, several other breakthroughs, like novel cell viability assays, are likely to drive the sector’s growth during the forecast period.
So, we find out that some other advances, such as novel cell viability assays, are expected to provide a positive impetus to the development of the industry within the forecast period.
For instance, Osaka University scientists developed biomaterial using stem cells that could cure degenerative intervertebral disc (IVD) disease associated with back pain and other spinal disorders during the April-May-June quarter of FY22. These chondrocytes are derived from stem cells, leading to the production of collagen-supporting cartilage tissue that has been implanted into a rat model of IVD degeneration, resulting in the restoration of spinal mechanical properties back to control levels and, therefore, will fuel market growth in the near term.
In March 2022, Promega Corporation announced its strategic collaboration with FUJIFILM Cellular Dynamics Inc. on novel assay development for drug discovery. The multi-year license agreement between Promega, a global leader in bioassay technologies, and FUJIFILM Cellular Dynamics includes an extensive range of highly customized iPSCs combined with Promega biosensor and intracellular bioluminescent reporter capabilities for use in novel assay development throughout the drug discovery process by researchers and scientists.
The growing use of cell viability assays for the discovery of drugs is driving Market CAGR for Cell Viability Assays. The existence of living or viable cells is referred to as cell viability, and it is thought to be a sign of good cell health. Viability levels are frequently altered in studies as a result of the action of chemical or physical agents, as in toxicity experiments. Cell viability assays (CVAs) are widely utilized in the pharmaceutical and healthcare sectors because they can be used to assess how cells would react to any pathogenic agent or medication.
Cell viability assays are becoming more often used in drug discovery and treatment programs as a result of the COVID-19 pandemic. For instance, Calidi Biotherapeutics Inc. declared in August 2020 that Personalized Stem Cells, Inc.'s IND (investigational new drug) application had been approved by the US FDA. The IND that was submitted was for the use of stem cells in the treatment of individuals with COVID-19 and pneumonia. Therefore, the usage of cell viability assay for understanding the reaction of living cells and viability for any line of treatment has been greatly ignited by the rise in cellular-based therapies for the treatment of Covid-19 infection.
The development of cell-based medicines is receiving more attention, which is propelling market expansion. Industry development is being aided by rising FDA approvals, scientific trials, and strategic activities like partnerships between important market participants. For instance, the FDA approved Abecma (idecabtagene vicleucel), in March 2021. In addition, CRISPR Therapeutics and ViaCyte, Inc. reported in February 2022 that the Phase 1 trial for a new gene-edited treatment for Type 1 Diabetes had dosed its first patient. These activities are anticipated to fuel industry expansion during the anticipated years
Additionally, increasing financing for stem cell research from various governments and industry participants is projected to create new market expansion prospects. For instance, the Federal Minister for Health and Aged Care, Hon. Greg Hunt, provided money totaling USD 18 million to the 2020 Stem Cell Mission in June 2021. The motive is to enhance health outcomes through the development and delivery of new, safe, and efficient stem cell treatments. Additionally, Curi Bio obtained investment in the amount of USD 10 million in January 2022 for a drug discovery platform that focuses on stem cells. Therefore, it is anticipated that the market will be driven during the study period by the growing emphasis on stem cell research. Thus, driving the Cell Viability Assays market revenue.
The market segments of Cell Viability Assays, based on the cell type, is divided into human cells, microbial cells, and animal cells. The microbial cells category dominated the market. The Microbial Cell Viability Assay offers a technique for counting the number of living microorganisms in a culture based on measuring the amount of ATP present. A single reagent (BacTiter-GloTM Reagent) is added to bacterial cells that have been grown in media for the homogeneous assay, and the luminescence is then measured.
Based on the application of Cell Viability Assays, the  Cell Viability Assays market segmentation includes stem cell research. The category with the biggest share and the quickest projected CAGR during the projection period is stem cell research. In recent years, the study of stem cells has evolved and shown great promise. The market's leading companies are working to create cutting-edge devices to aid in the research. For instance, Beckman Coulter Life Sciences introduced the AQUIOS STEM System, a revolutionary stem cell analysis solution, in May 2022.
The  Cell Viability Assays market segmentation, based on product, includes instruments, and consumables. The market was dominated by the consumables category. During the projected period, the segment is also expected to grow at the fastest rate. The usefulness of consumables in numerous pharmaceutical and biopharmaceutical, diagnostic, and stem cell research applications can be credited to this. Additionally, several market participants are providing a large selection of non-toxic, ready-to-use, and high-quality results-immediate cell viability assay reagents. For instance, Thermo Fisher Scientific, Inc.'s alamarBlue cell viability reagent is a non-toxic, ready-to-use reagent solution that serves as a cell health indicator by quantitatively measuring viability through consumption of the declining power of live cells.
Figure 1 Â Cell Viability Assays Market, by Product, 2022 & 2032 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. During the projected period, the North American Cell Viability Assays market is expected to dominate over the course of the forecasted period. This significant increase in investment initiatives by the government, the rise in the prevalence of chronic diseases like cancer, and the presence of a top-notch infrastructure for clinical and laboratory research in North America are all factors that contribute to this significant share.
Further, the major countries studied in the market report are The US, Canada, German, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 Â CELL VIABILITY ASSAYS MARKET SHARE BY REGION 2022 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Asia Pacific Cell Viability Assays market accounts for the fastest market share due to the increased regional need for innovative medicines. Other elements promoting regional prosperity include escalating government expenditure in R&D and quickening infrastructure growth. Moreover, the China market of Cell Viability Assays held the largest market share, and the India market of Cell Viability Assays was the quickest-growing market in the Asia-Pacific region.
The Europe Cell Viability Assays Market is expected to expand at the quickest CAGR from 2023 to 2032. This is due to the expansion of stem cell research, the growing demand for early and precise identification of chronic diseases, and the availability of well-established clinical and healthcare infrastructure in the area. Further, the Canada market of Cell Viability Assays was the fastest-growing region in the market, and the German market of Cell Viability Assays held a substantial share of the market.
Cell Viability Assays Key Market Players & Competitive Insights
Leading market players are investing capital and resources across research and development to extend their product offerings, this is expected to help the Cell Viability Assays market, grow even more. Market leaders and manufacturers are also adopting various strategies to expand their worldwide footprint, with important market developments including new product developments & launches, contracts & agreements, mergers & acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Cell Viability Assays industry must offer cost-effective items.
The manufacturers are making use of locally available resources to minimize the production costs which will aid the growth of the  Cell Viability Assays industry to benefit clients and increase the market sector. In recent years, the Cell Viability Assays industry has offered some of the most significant advantages to medicine. Major players in the Cell Viability Assays Market, including Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, GE Healthcare, Danaher Corporation, Becton Dickinson & Company, Promega Corporation, Biotium, Abcam plc, Creative Bioarray, and others, are attempting to increase market demand by investing in research and development operations.
A manufacturer and distributor of medical equipment, reagents, and instruments is Becton Dickinson and Co. (BD). Syringes and pen needles, intravenous catheters, infusion pumps, disposables, automated medication dispensing, and supply management systems, pre-fillable drug delivery systems, respiratory ventilation and diagnostic equipment and consumables, items for the secure collection and transportation of diagnostic specimens, instruments and reagent systems to detect a variety of infectious diseases and cancers, and clinical research tools are among its main products. Researchers working in the field of life sciences, hospitals, clinics, the pharmaceutical sector, and the general public can all benefit from BD's products. In February 2022, A privately held company with its headquarters in Salamanca, Spain, Cytognos specializes in flow cytometry solutions for blood cancer diagnosis, minimal residual disease (MRD) detection, and immune monitoring research for blood diseases. Today, BD, a leading  medical technology company, announced that it has successfully acquired Cytognos.
GE Healthcare Technologies Inc. (GE HealthCare) is a leading  provider of medical devices, specializing in the design, development, production, and distribution of diagnostic imaging, clinical systems, drug discovery, biopharmaceutical production, cellular technologies, imaging agents for use in medical scanning, and a variety of healthcare IT products. Additionally, GE HealthCare offers services including computerized data management, performance enhancement, performance solutions, and remote diagnosis and repair services for medical devices made by the business and others. In June 2021, GE Healthcare presented new molecular imaging products and solutions at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 summer conference, along with new chances to increase reach to radioactive tracers & pharmaceutical imaging agents.
 Key Companies in the market of Cell Viability Assays include
Cell Viability Assays Industry Developments
March 2022Â In San Diego, California, Biovica decided to open a CLIA laboratory. A location has been chosen, and a lease has been agreed for the building. Following approval, the lab will make DiviTumTKa-analysis available to customers of Biovica in the US.
June 2022Â Aura CL, the next generation of its instrument series, was introduced by Halo Labs, a well-known life science equipment business. In a single assay, Aura CL can count cells, identify therapeutic cells, and assess cell viability.
| Report Attribute/Metric | Details |
| Market Size 2024 | Â Â 2.24 (USD Billion) |
| Market Size 2025 | Â Â 2.43 (USD Billion) |
| Market Size 2034 | Â Â 5.05 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | Â Â 8.50 % (2025 - 2034) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2034 |
| Historical Data | 2020 - 2024 |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Cell type, Application, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, GE Healthcare, Danaher Corporation, Becton Dickinson & Company |
| Key Market Opportunities | Growing number of cancer and heart-related diseases |
| Key Market Dynamics | Increase in investment for the development of healthcare infrastructure |
Cell Viability Assays Market Highlights:
Frequently Asked Questions (FAQ) :
The Cell Viability Assays market size was valued at USD 1.9 Billion in 2022.
The market is projected to grow at a CAGR of 8.50% during the forecast period, 2025-2034.
North America had the largest share of the market
The key players in the market are Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, GE Healthcare, Danaher Corporation, and Becton Dickinson & Company.
The instruments category dominated the market in 2022.
The microbial cell had the largest share of the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
